Physician profile
Luis E De Armas
NPI 1235329558
$5,038.20
in general payments reported to CMS, 2019-2025
23 companies · $625 in 2025
The $625 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $412 · 2021: $824 · 2022: $635 · 2023: $918 · 2024: $917 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,658.41 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $604.49 | 2022-2025 | |
| Lilly USA, LLC | $519.23 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $451.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $346.92 | 2019-2020 | |
| Pfizer INC. | $238.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $181.59 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astrazeneca Uk Limited | $165.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $150.69 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.30 | 2023-2025 | Jardiance |
| Amgen INC. | $138.05 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $103.68 | 2021-2025 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $103.04 | 2023-2024 | Ingrezza |
| Amneal Pharmaceuticals LLC | $92.55 | 2019-2021 | |
| Novo Nordisk INC | $74.06 | 2024-2025 | Rybelsus, Ozempic |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.37 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.31 | 2024 | Zoryve |
| Cranial Technologies, INC | $12.76 | 2021 | |
| Kaleo, INC. | $12.50 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis De Armas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.